Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation
- PMID: 15184539
- DOI: 10.1099/jmm.0.45557-0
Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation
Abstract
Studies of the prevalence of Burkholderia cepacia complex species amongst cystic fibrosis (CF) patients in different geographical regions, and the association between cross-infection and putative transmissibility markers, will further our understanding of these organisms and help to address infection-control issues. In this study, B. cepacia complex isolates from CF patients in different regions of Europe were analysed. Isolates were examined for B. cepacia complex species and putative transmissibility markers [cable pilin subunit gene (cblA) and the B. cepacia epidemic strain marker (BCESM)]. Sporadic and cross-infective strains were identified by random amplification of polymorphic DNA (RAPD). In total, 79% of patients were infected with Burkholderia cenocepacia (genomovar III), 18% with Burkholderia multivorans (genomovar II) and less than 5% of patients with B. cepacia (genomovar I), Burkholderia stabilis (genomovar IV) or Burkholderia vietnamiensis (genomovar V). The cblA and BCESM transmissibility markers were only detected in strains of B. cenocepacia. The BCESM was a more sensitive marker for transmissible B. cenocepacia strains than cblA, although sporadic B. cenocepacia strains containing the BCESM, but lacking cblA, were also observed. Furthermore, clusters of cross-infection with transmissibility marker-negative strains of B. multivorans were identified. In conclusion, B. cenocepacia was the greatest cause of cross-infection, and the most widely distributed B. cepacia complex species, within these CF populations. However, cross-infection was not exclusive to B. cenocepacia and cblA and the BCESM were not absolute markers for transmissible B. cenocepacia, or other B. cepacia complex strains. It is therefore suggested that CF centres cohort patients based on the presence or absence of B. cepacia complex infection and not on the basis of transmissibility marker-positive B. cenocepacia as previously suggested.
Similar articles
-
Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom.J Clin Microbiol. 2000 May;38(5):1763-6. doi: 10.1128/JCM.38.5.1763-1766.2000. J Clin Microbiol. 2000. PMID: 10790095 Free PMC article.
-
Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis.Am J Respir Crit Care Med. 2001 Jul 1;164(1):92-6. doi: 10.1164/ajrccm.164.1.2011153. Am J Respir Crit Care Med. 2001. PMID: 11435245
-
Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center.J Clin Microbiol. 2004 Apr;42(4):1491-7. doi: 10.1128/JCM.42.4.1491-1497.2004. J Clin Microbiol. 2004. PMID: 15070994 Free PMC article.
-
[Epidemiology of infections associated to "Burkholderia cepacia complex" in the course of cystic fibrosis].Arch Pediatr. 2004 Apr;11(4):360-6. doi: 10.1016/j.arcped.2003.12.024. Arch Pediatr. 2004. PMID: 15139322 Review. French.
-
Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence.Clin Microbiol Infect. 2010 Jul;16(7):821-30. doi: 10.1111/j.1469-0691.2010.03237.x. Clin Microbiol Infect. 2010. PMID: 20880411 Review.
Cited by
-
Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Semin Respir Crit Care Med. 2015 Apr;36(2):299-320. doi: 10.1055/s-0035-1547347. Epub 2015 Mar 31. Semin Respir Crit Care Med. 2015. PMID: 25826595 Free PMC article. Review.
-
Refractory Burkholderia cepacia bacteraemia from a consolidation pneumonia lasting more than 7 weeks, successfully treated with systemic antibiotics and nebulised meropenem.BMJ Case Rep. 2019 Aug 2;12(8):e229566. doi: 10.1136/bcr-2019-229566. BMJ Case Rep. 2019. PMID: 31377717 Free PMC article.
-
Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre.Eur J Clin Microbiol Infect Dis. 2006 Mar;25(3):175-80. doi: 10.1007/s10096-006-0099-x. Eur J Clin Microbiol Infect Dis. 2006. PMID: 16501927
-
Identification of the flagellin glycosylation system in Burkholderia cenocepacia and the contribution of glycosylated flagellin to evasion of human innate immune responses.J Biol Chem. 2014 Jul 4;289(27):19231-44. doi: 10.1074/jbc.M114.562603. Epub 2014 May 19. J Biol Chem. 2014. PMID: 24841205 Free PMC article.
-
Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.PLoS One. 2017 Jun 29;12(6):e0179776. doi: 10.1371/journal.pone.0179776. eCollection 2017. PLoS One. 2017. PMID: 28662114 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical